scholarly journals Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus

2020 ◽  
Vol 11 (4) ◽  
pp. 951-964 ◽  
Author(s):  
Masako Saito ◽  
Atsunori Kaibara ◽  
Takeshi Kadokura ◽  
Junko Toyoshima ◽  
Satoshi Yoshida ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Sglt2 Inhibitor ◽  
Glucose Lowering ◽  
Model Based ◽  
Sodium Glucose Cotransporter

Dapagliflozin for heart failure – is it a class effect?

2020 ◽  
Author(s):  
Gerard Marshall Raj ◽  
Mukta Wyawahare
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Sglt2 Inhibitor ◽  
Therapeutic Application ◽  
Glucose Lowering ◽  
Reduced Ejection Fraction ◽  
Beneficial Effects

Dapagliflozin, an SGLT2 inhibitor used in the management of Type 2 diabetes mellitus, has been recently approved for the control of worsening cardiovascular events, including deaths and hospitalizations, in adults with heart failure with reduced ejection fraction. Previously, canagliflozin had a label change with regards to its additional usage in the reduction of risk of hospitalization for heart failure in patients with both Type 2 diabetes mellitus and diabetic nephropathy with albuminuria. On the other hand, the therapeutic application of empagliflozin and ertugliflozin in heart failure is yet to be delineated comprehensively. The beneficial effects of these SGLT2 inhibitors, dapagliflozin in particular, in heart failure are found to be independent of neither the glucose-lowering nor the SGLT2 inhibiting effects.

scholarly journals Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension

2019 ◽  
Author(s):  
Elias A Sanidas ◽  
Dimitrios P Papadopoulos ◽  
Erifili Hatziagelaki ◽  
Charalampos Grassos ◽  
Maria Velliou ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Arterial Hypertension ◽  
Sglt2 Inhibitors ◽  
Glucose Lowering ◽  
Sodium Glucose Cotransporter ◽  
Robust Evidence ◽  
Oral Antihyperglycemic Drugs

Abstract Sodium glucose cotransporter 2 (SGLT2) inhibitors represent a novel class of oral antihyperglycemic drugs that have been approved over the last decade for the management of type 2 diabetes mellitus. Except the glucose-lowering effects, robust evidence also suggests that SGLT2 inhibitors confer benefits in cardiovascular system. The purpose of this review was to investigate the effects of SGLT2 inhibitors across the spectrum of arterial hypertension.

scholarly journals Effective SGLT2 Inhibitor for Patient with Type 2 Diabetes Mellitus (T2DM) and Depression

2020 ◽  
Vol 2 (S1) ◽  
pp. 26-32
Author(s):  
Shimizu E ◽  
Takehisa Y ◽  
Bando H ◽  
Fujita M ◽  
Kusaka Y ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Female Patient ◽  
Diabetes Care ◽  
Sglt2 Inhibitor ◽  
Glucose Variability ◽  
Diabetic Control ◽  
Sodium Glucose Cotransporter

The case was a 55-year-old female patient with depression for 5 years and type 2 diabetes mellitus (T2DM) for 3 years. She has received anti-depressant and anti-hyperglycemic agents (OHAs). Approximately 1 year ago, her diabetic control became exacerbated without specific triggers. She was started to given Ipragliflozin L-Proline as Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. After that, her glucose variability and depression had been improved. According to the previous reports, SGLT-2 inhibitors seem to have anti-depression efficacy for diabetes. The case has been followed up in detail, and this report is expected to be a useful reference for diabetes care.

Sign in / Sign up

Export Citation Format

Share Document